SG Americas Securities
ACRV icon

SG Americas Securities’s Acrivon Therapeutics ACRV Stock Holding History

SG Americas Securities’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,265
Closed -$18K – 3353
2025
Q2 		$18K Buy
+15,265
New +$20.9K ﹤0.01% 2834

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SG Americas Securities's ACRV Position: Q3 2025 in Review

SG Americas Securities sold out of Acrivon Therapeutics (ACRV) in Q3 2025, closing a stake of 15,265 shares — an estimated $18K sold.

SG Americas Securities first reported a position in ACRV in Q2 2025 and held it in 1 quarter. The position peaked at $18K in Q2 2025. 48 funds tracked by Wall St. Rank hold ACRV as of Q3 2025.

  • SG Americas Securities reported no remaining Acrivon Therapeutics position as of Q3 2025 after selling out during the quarter.
  • SG Americas Securities sold 15,265 Acrivon Therapeutics shares in Q3 2025, an estimated $18K.
  • SG Americas Securities first reported a position in Acrivon Therapeutics in Q2 2025 and held it in 1 quarter.
  • SG Americas Securities's Acrivon Therapeutics position peaked at $18K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2025.

Based on SG Americas Securities's 13F filing for Q3 2025, filed 23 Oct 2025.